SPOTlight on GLOW

Sarah Derks; Hanneke W. M. van Laarhoven

doi:10.1016/j.xcrm.2023.101233

SPOTlight on GLOW

Sarah Derks^*
, Hanneke W. M. van Laarhoven

^*Corresponding author for this work

Department of Plastic, Reconstructive and Hand Surgery, Amsterdam UMC (Location VU), Amsterdam, The Netherlands
Amsterdam UMC
Oncode Institute, 3521 AL, Utrecht, The Netherlands
Oncode Institute
University of Amsterdam

Research output: Contribution to journal › Comment/Letter to the editor › Academic

18 Downloads (Pure)

Abstract

The GLOW randomized double-blind phase 3 trial1 shows that Claudin-18.2 targeting antibody zolbetuximab combined with capecitabine and oxaliplatin improves outcome compared to placebo and chemotherapy as first-line treatment in Claudin-18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinomas.

Original language	English
Article number	101233
Journal	Cell Reports Medicine
Volume	4
Issue number	10
DOIs	https://doi.org/10.1016/j.xcrm.2023.101233
Publication status	Published - 17 Oct 2023

Access to Document

10.1016/j.xcrm.2023.101233

Spotlight-on-glow.pdfFinal published version, 200 KBLicence: CC BY

Cite this

@article{5174f0dd1c0f4ec59e5edea30cb2f17d,

title = "SPOTlight on GLOW",

abstract = "The GLOW randomized double-blind phase 3 trial1 shows that Claudin-18.2 targeting antibody zolbetuximab combined with capecitabine and oxaliplatin improves outcome compared to placebo and chemotherapy as first-line treatment in Claudin-18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinomas.",

author = "Sarah Derks and \{van Laarhoven\}, \{Hanneke W. M.\}",

note = "Publisher Copyright: {\textcopyright} 2023 The Author(s)",

year = "2023",

month = oct,

day = "17",

doi = "10.1016/j.xcrm.2023.101233",

language = "English",

volume = "4",

journal = "Cell Reports Medicine",

issn = "2666-3791",

publisher = "Cell Press",

number = "10",

}

TY - JOUR

T1 - SPOTlight on GLOW

AU - Derks, Sarah

AU - van Laarhoven, Hanneke W. M.

PY - 2023/10/17

Y1 - 2023/10/17

N2 - The GLOW randomized double-blind phase 3 trial1 shows that Claudin-18.2 targeting antibody zolbetuximab combined with capecitabine and oxaliplatin improves outcome compared to placebo and chemotherapy as first-line treatment in Claudin-18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinomas.

AB - The GLOW randomized double-blind phase 3 trial1 shows that Claudin-18.2 targeting antibody zolbetuximab combined with capecitabine and oxaliplatin improves outcome compared to placebo and chemotherapy as first-line treatment in Claudin-18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinomas.

UR - https://www.scopus.com/pages/publications/85173903249

U2 - 10.1016/j.xcrm.2023.101233

DO - 10.1016/j.xcrm.2023.101233

M3 - Comment/Letter to the editor

C2 - 37852180

SN - 2666-3791

VL - 4

JO - Cell Reports Medicine

JF - Cell Reports Medicine

IS - 10

M1 - 101233

ER -

SPOTlight on GLOW

Abstract

Access to Document

Other files and links

Fingerprint

Cite this